RSR13
efaproxiral
Treatment for Brain Metastases in patients with Breast CancerAllos NDA To Be Reviewed By FDA Advisory Committee
WESTMINSTER, Colo., March 12, 2004 – Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) plans to review the company’s investigational radiation sensitizer, RSR13 (efaproxiral), on May 3, 2004. The company has submitted a New Drug Application (NDA) to the FDA seeking approval to market RSR13 (efaproxiral) as an adjunct to whole brain radiation therapy for the treatment of patients with brain metastases originating from breast cancer. Information regarding the ODAC panel is now available via the FDA Hotline at 1-800-741-8138 and will soon be posted to the Federal Register.
On February 2, 2004, the FDA accepted for priority review the company’s New Drug Application (NDA 21-661) seeking approval to market RSR13 as an adjunct to whole brain radiation therapy for the treatment of patients with brain metastases originating from breast cancer. The FDA has established a target date of June 4, 2004 to take action on the NDA.
“We welcome the additional review and insight the FDA’s outside scientific advisors will provide at the ODAC hearing,” said Michael E. Hart, President and CEO of Allos Therapeutics, Inc. “The recent acceptance for priority review of our NDA exemplifies our ongoing cooperative efforts with the FDA.”
About RSR13 (efaproxiral)
RSR13 (efaproxiral) is the first synthetic small molecule designed
to “sensitize” hypoxic (oxygen-deprived) areas of
tumors prior to radiation therapy by facilitating the release of
oxygen from hemoglobin, the oxygen-carrying protein contained
within red blood cells, and increasing the level of oxygen in
tumors. The presence of oxygen in tumors is an essential element
for the effectiveness of radiation therapy in the treatment of
cancer. By increasing tumor oxygenation at the time of treatment,
RSR13 (efaproxiral) has the potential to enhance the efficacy of
standard radiation therapy. Unlike chemotherapeutics or other
radiation sensitizers, RSR13 (efaproxiral) does not have to cross
the blood brain barrier or enter the tumor to be effective.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. is a biopharmaceutical company focused on
developing and commercializing innovative drugs for improving
cancer treatments. The company’s lead clinical candidate,
RSR13 (efaproxiral), is a synthetic small molecule that has the
potential to sensitize hypoxic (oxygen deprived) tumor tissues and
enhance the efficacy of standard radiation therapy. In addition,
Allos is developing PDX, an injectable small molecule
chemotherapeutic agent that has a superior potency and toxicity
profile relative to methotrexate and other dihydrofolate reductase,
or DHFR, inhibitors.
For further information, please visit www.allos.com.
Related Articles:
Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and Europe - June 16, 2004
Allos Therapeutics Receives FDA Approvable Letter for RSR13 (efaproxiral) - June 2, 2004
FDA Accepts Allos New Drug Application with Priority Review for RSR13 in Brain Metastases from Breast Cancer - February 3, 2004
New Drug Applications Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
